Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.43 |
| ▸ | ESRRG | P62508 | 2/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | ESRRB | O95718 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11285207 | 0.86 | KCNH2 (0.58) | KCNH2SIGMAR1GPR84GRIA4TSHR | |
| SCHEMBL7456580 | 0.85 | KCNH2 (0.59) | KCNH2SIGMAR1GPR84GRIA4TSHR | |
| SCHEMBL17023799 | 0.85 | KCNH2 (0.61) | KCNH2SIGMAR1GPR84GRIA4TSHR | |
| SCHEMBL1204683 | 0.80 | TSHR (0.48) | KCNH2SIGMAR1TSHRSLC13A5TP53 | |
| SCHEMBL31573982 | 0.80 | KCNH2 (0.67) | KCNH2SIGMAR1GRIA4TSHRSLC13A5 | |
| SCHEMBL9860834 | 0.79 | GFER (0.42) | — | |
| SCHEMBL547138 | 0.78 | KCNH2 (0.53) | KCNH2SIGMAR1GRIA4TSHRSLC13A5 | |
| SCHEMBL14838173 | 0.78 | KCNH2 (0.53) | KCNH2SIGMAR1GPR84GRIA4TSHR | |
| SCHEMBL3636537 | 0.76 | TAAR1 (0.61) | KCNH2DAOCNR1 | |
| SCHEMBL7559765 | 0.76 | KCNH2 (0.52) | KCNH2SIGMAR1GPR84GRIA4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716296-B | Efficient halogenation synthesis method of alkyl halide | 润药仁智(北京)科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2022-09-27 | — | — | US | disclosed |
| CN-114716296-A | Efficient halogenation synthesis method of alkyl halide | 北京大学 | 2022-07-08 | — | — | CN | disclosed |
| US-20220073507-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-03-10 | — | — | US | disclosed |
| CN-112351983-A | Substituted propionamides as inhibitors of nucleases | 马萨里克大学 | 2021-02-09 | — | — | CN | disclosed |
| EP-3556756-B1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2020-10-07 | — | — | EP | disclosed |
| EP-3556756-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | Masarykova univerzita (CZ) | 2019-10-23 | — | — | EP | disclosed |
| CN-109232175-A | A kind of preparation method of chloroethyl substituted aromatic compound | 四川理工学院 | 2019-01-18 | — | — | CN | disclosed |
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-27 | — | — | US | disclosed |
| US-20090170911-A1 | NOVEL AZOLE COMPOUND | AJINOMOTO CO. INC (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20090170911-A1 | NOVEL AZOLE COMPOUND | AJINOMOTO CO. INC (JP) | 2009-07-02 | — | — | US | disclosed |
| US-5486533-A | DIAZOLE OR TRIAZOLES WITH SILFIDES | UNIROYAL CHEMICAL COMPANY, INC. (US) | 1996-01-23 | — | — | US | disclosed |
| EP-0663904-A1 | FUNGICIDAL SUBSTITUTED AZOLE DERIVATIVES | UNIROYAL CHEMICAL COMPANY, Inc. (US) | 1995-07-26 | — | — | EP | disclosed |
| WO-1994008978-A1 | FUNGICIDAL SUBSTITUTED AZOLE DERIVATIVES | UNIROYAL CHEMICAL COMPANY, INC. (US) | 1994-04-28 | — | — | WO | disclosed |
| US-4178327-A | FIREPROOFING | THE DOW CHEMICAL COMPANY (US) | 1979-12-11 | — | — | US | disclosed |
| US-4054733-A | MOLDING MATERIALS | THE DOW CHEMICAL COMPANY (US) | 1977-10-18 | — | — | US | disclosed |
| US-3998895-A | PREPARATION OF POLYCHLOROALKENYL AROMATIC COMPOUNDS | UOP INC. (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170911-A1 | NOVEL AZOLE COMPOUND | LPAR1, LPAR2, LPAR3 | KCNH2 1103/4885SIGMAR1 1429/4885GPR84 39/4885 |
| US-20220073507-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | DNASE1, RNASEH1, FEN1 | KCNH2 3264/4885SIGMAR1 3672/4885GPR84 4547/4885 |
| US-20150238473-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | KCNH2 1413/4885SIGMAR1 4344/4885GPR84 4303/4885 |
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | DNASE1, RNASEH1, FEN1 | KCNH2 3264/4885SIGMAR1 3672/4885GPR84 4547/4885 |
| US-10004701-B2 | Methods and compositions for treating infection | MMP8, IFNG, MPO | KCNH2 1413/4885SIGMAR1 4344/4885GPR84 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.